Tiziana Life Sciences (TLSA) Competitors $2.42 +0.13 (+5.46%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. PRAX, AVDL, PAHC, PHVS, ARDX, GPCR, AMPH, VERV, SYRE, and AKBAShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), Spyre Therapeutics (SYRE), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Its Competitors Praxis Precision Medicines Avadel Pharmaceuticals Phibro Animal Health Pharvaris Ardelyx Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Akebia Therapeutics Tiziana Life Sciences (NASDAQ:TLSA) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Do insiders & institutionals hold more shares of TLSA or PRAX? 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is TLSA or PRAX more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -2,137.48%. Tiziana Life Sciences' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Praxis Precision Medicines -2,137.48%-59.42%-54.64% Do analysts rate TLSA or PRAX? Praxis Precision Medicines has a consensus target price of $95.22, indicating a potential upside of 94.91%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has higher earnings & valuation, TLSA or PRAX? Tiziana Life Sciences has higher earnings, but lower revenue than Praxis Precision Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/APraxis Precision Medicines$8.55M116.39-$182.82M-$10.72-4.56 Which has more volatility & risk, TLSA or PRAX? Tiziana Life Sciences has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Does the media refer more to TLSA or PRAX? In the previous week, Praxis Precision Medicines had 24 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 24 mentions for Praxis Precision Medicines and 0 mentions for Tiziana Life Sciences. Praxis Precision Medicines' average media sentiment score of 0.49 beat Tiziana Life Sciences' score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Overall Sentiment Tiziana Life Sciences Neutral Praxis Precision Medicines Neutral SummaryPraxis Precision Medicines beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks. Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$280.44M$2.97B$5.48B$9.54BDividend YieldN/A2.41%4.71%4.14%P/E RatioN/A17.1428.7323.79Price / SalesN/A306.13439.6695.98Price / CashN/A42.6035.6858.35Price / Book60.387.988.155.60Net Income-$11.86M-$54.52M$3.25B$265.17M7 Day Performance1.90%-1.08%-0.99%-0.94%1 Month Performance56.82%13.37%5.25%4.95%1 Year Performance121.56%11.25%28.32%23.30% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.2959 of 5 stars$2.42+5.5%N/A+124.5%$280.44MN/A0.008PRAXPraxis Precision Medicines1.7195 of 5 stars$51.09-5.5%$94.11+84.2%-10.7%$1.10B$8.55M-4.77110Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAVDLAvadel Pharmaceuticals2.8232 of 5 stars$11.26+1.6%$18.33+62.8%-30.9%$1.07B$169.12M-41.7070Positive NewsUpcoming EarningsPAHCPhibro Animal Health4.2696 of 5 stars$27.14+3.9%$24.40-10.1%+53.9%$1.06B$1.02B34.801,940Positive NewsPHVSPharvaris2.1425 of 5 stars$21.24+6.2%$36.20+70.4%+22.0%$1.05BN/A-7.0630Upcoming EarningsARDXArdelyx4.2703 of 5 stars$4.39+1.4%$10.88+147.7%-12.0%$1.04B$333.61M-19.9590News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGPCRStructure Therapeutics2.2354 of 5 stars$16.78-4.6%$76.17+353.9%-53.7%$1.01BN/A-19.29136News CoverageAMPHAmphastar Pharmaceuticals4.3224 of 5 stars$21.40+0.9%$32.33+51.1%-46.9%$999.82M$731.97M7.752,028News CoverageUpcoming EarningsVERVVerve Therapeutics3.4354 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110SYRESpyre Therapeutics2.2524 of 5 stars$16.16-0.6%$53.40+230.4%-35.1%$980.08M$890K-4.2973News CoveragePositive NewsAKBAAkebia Therapeutics3.7179 of 5 stars$3.76+1.1%$6.75+79.5%+213.9%$977.01M$160.18M-17.90430Upcoming Earnings Related Companies and Tools Related Companies PRAX Competitors AVDL Competitors PAHC Competitors PHVS Competitors ARDX Competitors GPCR Competitors AMPH Competitors VERV Competitors SYRE Competitors AKBA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our Partners[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
